Through their predictive analytics, Cigna can identify customers most likely to suffer from an overdose and can prompt interventions.
Pain management could be enhanced by research to develop a better understanding of chronic pain and development of new non-addictive pain treatments. To speed movement of non-addictive treatments through the clinical pipeline, a public-private HEAL partnership is planned.
Fremanezumab, an anti-CGRP monoclonal antibody, is currently being reviewed by the Food and Drug Administration (FDA) as a quarterly or monthly injection for the preventive treatment of migraine in adults.
Increased thirst and irritability are reported with prolonged fasting period, as well as detrimental physiological and metabolic effects. No increased risk of pulmonary aspiration was reported with a 1-hour clear fluid policy and studies demonstrated that the stomach was empty.
The effects of the US Drug Enforcement Administration's 2014 ruling to reschedule hydrocodone combination products on the trade in opioids through cryptomarkets was analyzed by researchers.
The researchers found that dexmedetomidine reduced the etomidate-induced sustained increase in α5 γ-aminobutyric acid type A receptor cell-surface expression (etomidate: 146.4 ± 51.6%; etomidate + dexmedetomidine: 118.4 ± 39.1% of control).
The researchers found that being age 65 years or older (40.9 versus 29.5%; P=.026), being in an ICU (medical ICU/cardiac ICU: 27.3 versus 3.4%; P<.001; surgical ICU: 18.1 versus 5.7%; P=.031), and having renal impairment (estimated glomerular filtration rate ≤60: 50 vs 28.4%; P=.034) were associated with opioid overdose.
The antiepileptic drug levetiracetam may represent an effective prophylactic treatment option for episodic migraine.
Electrical pulses are sent through small needles that are inserted in the ear to combat the early stages of detoxification, leading to stabilization.
Researchers assessed factors associated with post-discharge persistent opioid use of up to 6 months in a group of 86 children and adolescents (median age, 12 years) who had undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
The U.S. Food and Drug Administration has issued warnings to 9 online companies selling illegal opioid medications on 53 websites, in direct violation of the Federal Food, Drug, and Cosmetic Act.
The researchers found that liposomal bupivacaine was used in 21.2% of patients. Its use was not associated with a clinically meaningful reduction in inpatient opioid prescription, length of stay, or cost of hospitalization.
The researchers found that 168,315,458 patients filled IR formulations and 10,216,570 filled extended-release/long-acting (ER/LA) formulations.
A total of 858 adults with at least a 1-year history of migraine, 4 to 14 migraine headache days per month, and a mean of at least 2 migraine attacks per month within the past 3 months received once-monthly treatments for 6 months and were followed up for 5 months after the last injection.
Adult doses for migraine and headache treatments including barbiturates, ergot alkaloids, and NSAIDs.
The Agency is urging manufacturers to stop marketing OTC oral drug products containing benzocaine for teething to this patient population.
A standard of practice and educational intervention aimed to reduce intravenous opioids in favor of subcutaneous route resulted in reduced frequency of intravenous opioids.
There was a positive correlation for subsequent opioid overdose with successively greater numbers of prescribers or pharmacies or higher opioid quantities during the index period.
In this multicenter, double-blind, placebo-controlled trial, patients (N=409) were randomized 1:1:1 to a postoperative regimen of IV tramadol 50mg, IV tramadol 25mg, or placebo administered over 15 minutes at hours 0, 2, 4, and once every 4 hours thereafter (up to 13 doses).
The highest percentage of unused medications (70%) was seen for cystectomy, which was the most invasive surgery; the lowest percentage of unused medications was seen for cystoscopy-based procedures (37.5%).
The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).
Lucemyra, a selective alpha 2-adrenergic receptor agonist, works by reducing the release of norepinephrine and decreasing sympathetic tone.
In this randomized controlled trial, Fremanezumab slightly decreased the amount of headache free days in those with episodic migraines compared to placebo.